

1 ENGROSSED SENATE
2 BILL NO. 518

3 By: Alvord of the Senate

4 and

5 West (Kevin) of the House

6 An Act relating to medical marijuana packaging;
7 amending 63 O.S. 2021, Section 427.18, as last
8 amended by Section 144, Chapter 452, O.S.L. 2024 (63
O.S. Supp. 2024, Section 427.18), which relates to
packaging and labeling requirements; requiring
certain labeling; and providing an effective date.

10 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

11 SECTION 1. AMENDATORY 63 O.S. 2021, Section 427.18, as
12 last amended by Section 144, Chapter 452, O.S.L. 2024 (63 O.S. Supp.
13 2024, Section 427.18), is amended to read as follows:

14 Section 427.18. A. A medical marijuana business shall not
15 sell, transfer or otherwise distribute medical marijuana or medical
16 marijuana product that has not been packaged and labeled in
17 accordance with this section and rules promulgated by the Executive
18 Director of the Oklahoma Medical Marijuana Authority.

19 B. A medical marijuana dispensary shall return medical
20 marijuana and medical marijuana product that does not meet packaging
21 or labeling requirements in this section or rules promulgated
22 pursuant thereto to the entity who transferred it to the dispensary.
23 The medical marijuana dispensary shall document to whom the item was

1 returned, what was returned, and the date of the return, or dispose
2 of any usable marijuana that does not meet these requirements in
3 accordance with the Oklahoma Medical Marijuana and Patient
4 Protection Act.

5 C. 1. Medical marijuana packaging shall be packaged to
6 minimize its appeal to children and shall not depict images other
7 than the business name logo of the medical marijuana producer and
8 image of the product.

9 2. A medical marijuana business shall not place any content on
10 a container in a manner that reasonably appears to target
11 individuals under the age of twenty-one (21) including, but not
12 limited to, cartoon characters or similar images.

13 3. Labels on a container shall not include any false or
14 misleading statements.

15 4. No container shall be intentionally or knowingly labeled so
16 as to cause a reasonable patient confusion as to whether the medical
17 marijuana, medical marijuana concentrate or medical marijuana
18 product is a trademarked product or labeled in a manner that
19 violates any federal trademark law or regulation. The label on the
20 container shall include a warning that states the following:

21 a. "For use by licensed medical marijuana patients only",
22 and

23 b. "Keep out of reach of children"–, and

1 c. "Marijuana and marijuana products can impair
2 concentration, coordination, and judgment: a person
3 should not operate a motor vehicle while under the
4 influence of marijuana or marijuana products. The
5 ingestion of any amount of marijuana or marijuana
6 products before driving may result in criminal
7 prosecution for driving under the influence."

8 5. The label on the container shall not make any claims
9 regarding health or physical benefits to the patient.

10 6. The container itself may be clear in order to allow licensed
11 medical marijuana patients and licensed medical marijuana caregivers
12 the ability to view the product inside the container but shall be
13 child-resistant, as defined in Section 427.2 of this title.

14 7. At the point of sale and transfer of any medical marijuana,
15 medical marijuana concentrate, or medical marijuana products to a
16 licensed medical marijuana patient or licensed medical marijuana
17 caregiver, the dispensary shall place the medical marijuana, medical
18 marijuana concentrate, or medical marijuana products in an exit
19 package, as such term is defined in Section 427.2 of this title.

20 D. The Executive Director shall develop minimum standards for
21 packaging and labeling of medical marijuana, medical marijuana
22 concentrate, and medical marijuana products. Such standards shall
23 include, but not be limited to, the required contents of labels to
24 be affixed to all medical marijuana, medical marijuana concentrate,

1 and medical marijuana products prior to transfer to a licensed
2 patient or caregiver, which shall include, at a minimum:
3 1. THC and other cannabinoid potency, and terpenoid potency;
4 2. A statement indicating that the product has been tested for
5 contaminants;
6 3. One or more product warnings to be determined by the
7 Executive Director; and
8 4. Any other information the Executive Director deems
9 necessary.

SECTION 2. This act shall become effective November 1, 2025.

Passed the Senate the 27th day of March, 2025.

Presiding Officer of the Senate

Passed the House of Representatives the _____ day of _____,
6.

Presiding Officer of the House
of Representatives